PE106099A1 - Uso de derivados hidroxicumaranonas sustituidos como agentes antitumorales y antimetastasicos - Google Patents
Uso de derivados hidroxicumaranonas sustituidos como agentes antitumorales y antimetastasicosInfo
- Publication number
- PE106099A1 PE106099A1 PE1998000679A PE00067998A PE106099A1 PE 106099 A1 PE106099 A1 PE 106099A1 PE 1998000679 A PE1998000679 A PE 1998000679A PE 00067998 A PE00067998 A PE 00067998A PE 106099 A1 PE106099 A1 PE 106099A1
- Authority
- PE
- Peru
- Prior art keywords
- isopropilidencumaran
- piperidin
- substituted
- ona
- hydroxycumaranone
- Prior art date
Links
- 230000000259 anti-tumor effect Effects 0.000 title abstract 2
- VQTUMNNCKYTZSR-UHFFFAOYSA-N 3-hydroxy-3h-1-benzofuran-2-one Chemical class C1=CC=C2C(O)C(=O)OC2=C1 VQTUMNNCKYTZSR-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- IQRBPUVIUQDULO-UHFFFAOYSA-N 4-fluoro-n-piperidin-4-ylbenzamide Chemical compound C1=CC(F)=CC=C1C(=O)NC1CCNCC1 IQRBPUVIUQDULO-UHFFFAOYSA-N 0.000 abstract 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 2
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical class [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 abstract 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 abstract 1
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 abstract 1
- 229940122489 Urokinase-type plasminogen activator inhibitor Drugs 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 235000010290 biphenyl Nutrition 0.000 abstract 1
- 239000004305 biphenyl Substances 0.000 abstract 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical class C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 abstract 1
- 108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/83—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE AL USO DE COMPUESTOS DE FORMULA I PARA LA PREPARACION DE UN MEDICAMENTO ANTITUMORAL, DONDE R Y R` SON H, ALQUILO C1-C6, ESTIRILO, CICLOALQUILO C3-C6 O JUNTOS FORMAN CICLOALQUILO C3-C6; x ES 0 o 1; A ES -(CH2)n-, -CH2CH=CHCH2-, -CH2-CH=CH-CH=CH-CH2-, ENTRE OTROS; B ES -N(R1)-(CH2)m-N(R2)-, GRUPO (a, b), ENTRE OTROS; m ES 2-6; R1 ES H, METILO, ETILO, ENTRE OTROS; R2 ES ALQUILO C1-C6, BENCILO, NAFTILO, ENTRE OTROS; T ES -CH2-C�CH, -C�CH, -(CH2)p-R3, ENTRE OTROS; p ES 0-4; R3 ES FENILO, NAFTILO, BIFENILO OPCIONALMENTE SUSTITUIDO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 4-(4-(4-(4-FLUOROBENZAMIDO)PIPERIDIN)BUTOXI)-2-ISOPROPILIDENCUMARAN-3-ONA; 4-(3-(4-(4-FLUOROBENZAMIDO)PIPERIDIN)PROPOXI-2-ISOPROPILIDENCUMARAN-3-ONA. TAMBIEN SE REFIERE AL COMPUESTO I EXCEPTO BENZOCUMARANONAS 6-HIDROXI SUSTITUIDAS Y 4-(3-(4-(4-FLUOROBENZAMIDO)PIPERIDIN)PROPOXI)-2-ISOPROPILIDENCUMARAN-3-ONA. EL COMPUESTO I ES UN INHIBIDOR DEL ACTIVADOR PLASMINOGENO DEL TIPO DE LA UROQUINASA, AL UNIRSE A SU RECEPTOR (uPA/uPAR); POR LO QUE PUEDE TENER ACTIVIDAD ANTITUMORAL Y ANTIMETASTASICA
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97113190 | 1997-07-31 | ||
| EP98106946 | 1998-04-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE106099A1 true PE106099A1 (es) | 1999-11-11 |
Family
ID=26145681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1998000679A PE106099A1 (es) | 1997-07-31 | 1998-07-30 | Uso de derivados hidroxicumaranonas sustituidos como agentes antitumorales y antimetastasicos |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6200989B1 (es) |
| EP (1) | EP1012147B1 (es) |
| JP (1) | JP3241711B2 (es) |
| KR (1) | KR100343067B1 (es) |
| AR (1) | AR013374A1 (es) |
| AT (1) | ATE308535T1 (es) |
| AU (1) | AU745839B2 (es) |
| BR (1) | BR9811589A (es) |
| CA (1) | CA2296476A1 (es) |
| DE (1) | DE69832184D1 (es) |
| HR (1) | HRP20000031A2 (es) |
| HU (1) | HUP0004221A2 (es) |
| ID (1) | ID24525A (es) |
| IL (1) | IL134193A0 (es) |
| MA (1) | MA26528A1 (es) |
| NO (1) | NO20000366L (es) |
| PE (1) | PE106099A1 (es) |
| PL (1) | PL338614A1 (es) |
| TR (1) | TR200000272T2 (es) |
| UY (1) | UY25114A1 (es) |
| WO (1) | WO1999006387A2 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU736869B2 (en) * | 1999-01-30 | 2001-08-02 | Roche Diagnostics Gmbh | O-substituted hydroxycoumaranone derivatives as antitumor and antimetastatic agents |
| AU2002362030A1 (en) * | 2001-11-27 | 2003-06-10 | Fred Hutchinson Cancer Research Center | Methods for inhibiting deacetylase activity |
| WO2003051347A1 (en) * | 2001-12-19 | 2003-06-26 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Use of urokinase receptor antagonists to modulate ischemiareperfusion injury |
| WO2004076444A2 (en) * | 2003-02-25 | 2004-09-10 | F. Hoffmann-La Roche Ag | Novel hydroxycoumaranone derivatives as antitumor and antimetastatic |
| JP5247459B2 (ja) * | 2006-10-27 | 2013-07-24 | 国立大学法人 東京大学 | アミド化合物及びその塩、それを用いたバイオフィルム形成阻害剤、バイオフィルム剥離剤および殺菌剤 |
| US8258307B2 (en) | 2006-11-07 | 2012-09-04 | University Of Tokyo | Amide compound or salt thereof, and biofilm inhibitor, biofilm remover and disinfectant containing the same |
| GB2460915B (en) * | 2008-06-16 | 2011-05-25 | Biovascular Inc | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor |
| PT109740B (pt) * | 2016-11-14 | 2020-07-30 | Hovione Farmaciencia Sa | Processo para a preparação de brometo de umeclidínio |
| ES2919779T3 (es) | 2017-06-20 | 2022-07-28 | Imbria Pharmaceuticals Inc | Derivado de 1-[(2,3,4-trimetoxifenil)metil]-piperazina, composiciones del mismo y métodos para aumentar la eficiencia del metabolismo cardíaco |
| PT3684767T (pt) | 2017-09-22 | 2024-07-29 | Jubilant Epipad LLC | Compostos heterocíclicos como inibidores de pad |
| CA3076476A1 (en) | 2017-10-18 | 2019-04-25 | Jubilant Epipad LLC | Imidazo-pyridine compounds as pad inhibitors |
| US11629135B2 (en) | 2017-11-06 | 2023-04-18 | Jubilant Prodell Llc | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
| AU2018372211B2 (en) | 2017-11-24 | 2023-02-02 | Jubilant Episcribe LLC, | Heterocyclic compounds as PRMT5 inhibitors |
| CN111757739A (zh) | 2017-12-13 | 2020-10-09 | 普拉西斯生物技术有限责任公司 | 整合应激反应路径抑制剂 |
| JP7279063B6 (ja) | 2018-03-13 | 2024-02-15 | ジュビラント プローデル エルエルシー | Ｐｄ１／ｐｄ－ｌ１相互作用／活性化の阻害剤としての二環式化合物 |
| SG11202011014VA (en) * | 2018-06-05 | 2020-12-30 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| EP4497474A3 (en) | 2018-10-17 | 2025-04-23 | Imbria Pharmaceuticals, Inc. | Methods of treating rheumatic diseases using trimetazidine-based compounds |
| JP6611029B1 (ja) * | 2018-11-05 | 2019-11-27 | プキョン ナショナル ユニバーシティ インダストリ ユニバーシティ コーポレーション ファウンデーションＰｕｋｙｏｎｇ Ｎａｔｉｏｎａｌ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ｕｎｉｖｅｒｓｉｔｙ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ | 高周波超音波多焦点変換器、その製造装置、および製造方法 |
| CA3142748A1 (en) | 2019-06-12 | 2020-12-17 | Praxis Biotech LLC | Modulators of integrated stress response pathway |
| US11530184B2 (en) | 2020-06-30 | 2022-12-20 | Imbria Pharmaceuticals, Inc. | Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11780811B2 (en) | 2020-06-30 | 2023-10-10 | Imbria Pharmaceuticals, Inc. | Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11883396B2 (en) | 2021-05-03 | 2024-01-30 | Imbria Pharmaceuticals, Inc. | Methods of treating kidney conditions using modified forms of trimetazidine |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2901336A1 (de) * | 1979-01-15 | 1980-07-24 | Boehringer Mannheim Gmbh | Neue arylether, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel |
| DE3209271A1 (de) | 1982-03-13 | 1983-09-15 | Boehringer Mannheim Gmbh, 6800 Mannheim | Bicyclische phenolether, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel |
| WO1986001212A1 (en) * | 1984-08-13 | 1986-02-27 | Biotechnology Australia Pty. Ltd. | Minactivin |
| US5747458A (en) * | 1995-06-07 | 1998-05-05 | Chiron Corporation | Urokinase receptor ligands |
-
1998
- 1998-07-23 BR BR9811589-8A patent/BR9811589A/pt not_active Application Discontinuation
- 1998-07-23 KR KR1020007000941A patent/KR100343067B1/ko not_active Expired - Fee Related
- 1998-07-23 TR TR2000/00272T patent/TR200000272T2/xx unknown
- 1998-07-23 AT AT98943771T patent/ATE308535T1/de not_active IP Right Cessation
- 1998-07-23 EP EP98943771A patent/EP1012147B1/en not_active Expired - Lifetime
- 1998-07-23 IL IL13419398A patent/IL134193A0/xx unknown
- 1998-07-23 HR HR20000031A patent/HRP20000031A2/hr not_active Application Discontinuation
- 1998-07-23 WO PCT/EP1998/004619 patent/WO1999006387A2/en not_active Ceased
- 1998-07-23 AU AU91559/98A patent/AU745839B2/en not_active Ceased
- 1998-07-23 PL PL98338614A patent/PL338614A1/xx not_active Application Discontinuation
- 1998-07-23 JP JP2000505146A patent/JP3241711B2/ja not_active Expired - Fee Related
- 1998-07-23 CA CA002296476A patent/CA2296476A1/en not_active Abandoned
- 1998-07-23 DE DE69832184T patent/DE69832184D1/de not_active Expired - Lifetime
- 1998-07-23 HU HU0004221A patent/HUP0004221A2/hu unknown
- 1998-07-23 ID IDW20000173A patent/ID24525A/id unknown
- 1998-07-29 AR ARP980103732A patent/AR013374A1/es unknown
- 1998-07-29 UY UY25114A patent/UY25114A1/es not_active Application Discontinuation
- 1998-07-30 PE PE1998000679A patent/PE106099A1/es not_active Application Discontinuation
- 1998-07-31 MA MA25200A patent/MA26528A1/fr unknown
-
1999
- 1999-09-22 US US09/401,403 patent/US6200989B1/en not_active Expired - Fee Related
-
2000
- 2000-01-25 NO NO20000366A patent/NO20000366L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20000366D0 (no) | 2000-01-25 |
| AU9155998A (en) | 1999-02-22 |
| IL134193A0 (en) | 2001-04-30 |
| HUP0004221A2 (hu) | 2001-04-28 |
| JP2001512113A (ja) | 2001-08-21 |
| WO1999006387A3 (en) | 1999-04-22 |
| DE69832184D1 (de) | 2005-12-08 |
| ID24525A (id) | 2000-07-20 |
| ATE308535T1 (de) | 2005-11-15 |
| UY25114A1 (es) | 2001-01-31 |
| KR100343067B1 (ko) | 2002-07-03 |
| WO1999006387A2 (en) | 1999-02-11 |
| MA26528A1 (fr) | 2004-12-20 |
| PL338614A1 (en) | 2000-11-06 |
| TR200000272T2 (tr) | 2000-09-21 |
| AR013374A1 (es) | 2000-12-27 |
| EP1012147B1 (en) | 2005-11-02 |
| KR20010022362A (ko) | 2001-03-15 |
| AU745839B2 (en) | 2002-04-11 |
| NO20000366L (no) | 2000-01-25 |
| HRP20000031A2 (en) | 2000-10-31 |
| US6200989B1 (en) | 2001-03-13 |
| EP1012147A2 (en) | 2000-06-28 |
| BR9811589A (pt) | 2000-09-19 |
| JP3241711B2 (ja) | 2001-12-25 |
| CA2296476A1 (en) | 1999-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE106099A1 (es) | Uso de derivados hidroxicumaranonas sustituidos como agentes antitumorales y antimetastasicos | |
| CR10145A (es) | Derivados de tropano útiles en terapia (divisional exp. 6800) | |
| PE20020476A1 (es) | Derivados de glucopiranosiloxibencilbenceno y composiciones farmaceuticas que comprenden los mismos | |
| AR033306A1 (es) | Compuestos | |
| NO983970L (no) | Tricykliske forbindelser, deres fremstilling og anvendelse | |
| ES2062395T3 (es) | Nuevos compuestos de bencimidazol y su uso. | |
| MX9300031A (es) | Derivados de piperazina, procedimiento para su preparacion y composicion farmaucetica que los contiene. | |
| ES2123829T3 (es) | Derivados de 3-(5-tetrazolil-bencil)amino-piperidina y antagonistas de las taquiquininas. | |
| ES2187983T3 (es) | Derivados 1,2,3,4-tetrahidronaftaleno sustituidos. | |
| ES2174989T3 (es) | Pirido(3,2-e)pirazinonas con antiasmatica y procedimiento para su preparacion. | |
| AR035153A1 (es) | Derivados de carboxamidas y cetonas de dihidrobenzodioxina | |
| NO20025641D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
| NO924964L (no) | Tiazolidinforbindelser og fremgangsmaate til fremstilling derav | |
| AR025103A1 (es) | Quelantes quimicos para la reversion del bloqueo neuromuscular inducido por farmacos | |
| AR039651A1 (es) | Derivados de isoquinolina | |
| NO20000737D0 (no) | Tetrahydro <gamma>-karboliner | |
| MX9306310A (es) | Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| ES2106936T5 (es) | Derivados de carbazolona y procedimientos para su preparacion. | |
| ES2043863T3 (es) | Procedimiento para preparar derivados de la 1,2,5,6-tetrahidropiridina. | |
| ES8800934A1 (es) | Un procedimiento para la obtencion de derivados de bi- y triciclicos de piridona | |
| AR039122A1 (es) | Derivados de ftalimido como inhibidores de monoamino oxidasa b | |
| AR003137A1 (es) | Una composicion farmaceutica para tratar la leucemia | |
| PE25998A1 (es) | DERIVADOS DE OCTAHIDRO-PIRROLO(1,2-a)-PIRAZINA 2,7-SUSTITUIDOS | |
| AR035247A1 (es) | Derivados de piperidinacarboxamida, un procedimiento para su preparacion y las composiciones farmaceuticas que los contienen | |
| AR018675A1 (es) | Derivados de 3-(2-oxo-[1,3¿i¿]bipirrolidinil-3-ilidenometil)-cefem, una composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |